Citations

Clear

16 citation(s) found for "Olszanski, Anthony J".

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Johnson, Douglas, Albertini, Mark R. , Barker, C. A., Bateni, Sarah, Baumgartner, Joel, Bichakjian, Christopher, Boland, Genevieve , Chandra, Sunandana , Chen, David, Choi, Jacob, DiMaio, Dominick, Dronca, Roxana, Fleming, Martin D. , Galan, Anjela , Guild, Samantha, Hu-Lieskovan, Siwen, Karakousis, Giorgos, Kendra, Kari, Kiuru, Maija, Lange, Julie R., Lanning, Ryan, Logan, Theodore, Materin, Miguel, Nelson, Kelly, Olson, Daniel, Pa, Ott, Puzanov, Igor, Rothermel, Luke, Salama, April K., Shannon, Adrienne, Singh, Arun, Stacey, Andrew, Tsai, Katy, Wuthrick, Evan, Xing, Yan, McMillian, Nicole, Espinosa, Sara, Swetter, Susan M. , Johnson, Douglas B., Barker, Christopher A. , Baumgartner, Joel , Bhatia, Shailender , Bichakjian, Christopher K. , Chmielowski, Bartosz , DiMaio, Dominick J. , Guild, Samantha, Hu‐Lieskovan, Siwen , Karakousis, Giorgos C. , Kiuru, Maija H. , Lanning, Ryan M. , Logan, Theodore F. , Materin, Miguel Angel , Nelson, Kelly C., Olson, Daniel , Olszanski, Anthony J. , Puzanov, Igor , Rothermel, Luke D. , Salama, April K.S. , Sharma, Rohit , Wuthrick, Evan , McMillian, Nicole R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 15, 2026 | Volume: 24 | Issue: 6 | Pages: 272-277

10.6004/jnccn.2026.0027 | PMID 42297031 Get It

The NCCN Guidelines for Melanoma: Cutaneous provide strategies for the diagnosis, treatment, and follow-up of patients with cutaneous melanoma, which is among the most common cancers in the United States. The outcome of cutaneous melanoma is significantly influenced by stage at initial presentation. Generally, localized disease and smaller primary tumors have been associated with more favorable prognosis. Thus, the select content featured in this issue focuses on risk factors associated with cutaneous melanoma development and which should be considered during an initial assessment. These include (1) phenotypic predispositions, (2) personal medical history or comorbidities, (3) genetic predispositions, and (4) environmental factors.
A phase I/IIa, first-in-human, multicenter, monotherapy and combination therapy with nivolumab dose-finding study of [ 212 Pb]VMT01 melanocortin-1-receptor–targeted, image-guided, alpha-particle therapy in
Patel, Ravi , Mehr, Samuel, Arays, Ruta , Srinivas, Shyam M., Saigal, Kunal, Osman, Medhat, Puhlmann, Markus , Keefe, Stephen Michael, Yang, Wenjing, Hanna, Alaa , Kurup, Divya, Block, Matthew S. , Morris, Zachary Scott , Wahl, Richard L. , Lutzky, Jose , Mehr, Samuel H., Olszanski, Anthony J. , Menda, Yusuf , Srinivas, Shyam M., Osman, Medhat, Keefe, MD Stephen

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 9525-9525

10.1200/jco.2026.44.16_suppl.9525 Get It

9525 Background: Melanocortin-1 receptor (MC1R) is a novel target for radiopharmaceutical therapy and is highly expressed on melanoma tumor cells. VMT01 is an MC1R-targeted peptide. 203 Pb is used for patient selection via SPECT imaging. Peptide radiolabeling with 212 Pb delivers alpha-particle therapy. Here, we present data on the treatment of adult patients with MC1R-positive metastatic melanoma receiving [ 212 Pb]VMT01 either as a monotherapy or in combination with the programmed death-1 (PD-1) checkpoint inhibitor, nivolumab. Methods: This is an ongoing phase I/IIa, first-in-human, prospective, multicenter, open-label, radioactive dose-finding and dose-expansion trial. The objectives are to investigate safety, pharmacokinetics, dosimetry, and efficacy. Participants receive up to 3 treatment cycles with either [ 212 Pb]VMT01 3 mCi, 5 mCi, or 1.5 mCi monotherapy, or combination therapy with [ 212 Pb]VMT01 (1.5 mCi) + nivolumab (480 mg, Q4W) or [ 212 Pb]VMT01 (3 mCi) + nivolumab. Participants are evaluated for any DLTs for the first 6 weeks after cycle 1. Efficacy is assessed by RECIST v1.1 criteria by the investigator. Results: As of 24 December 2025, 26 participants (53.8% male; median age: 68 years [range: 27-81]) with MC1R-positive metastatic melanoma were enrolled. The median prior systemic therapies was 4. All 26 enrolled participants received ≥1 dose of [²¹²Pb]VMT01. No DLTs were reported. All SAEs (including one grade 5 SAE) were attributed to disease progression. Most TEAEs were grade 1 (19.2%) and grade 2 (34.6%). Grade 3 TEAEs occurred in 8 participants (30.8%), 5 on monotherapy and 3 on combination therapy (3 mCi + nivolumab). Of the 22 evaluable participants, 1 PR, 9 SD, and 12 PD were reported. Four participants had progression-free survival of ≥6 months. Conclusions: [ 212 Pb]VMT01 as a monotherapy and in combination with nivolumab was generally safe and well-tolerated in 26 enrolled participants, with antitumor activity observed at the 3 mCi dose level. These data may be supplemented with a more complete follow-up at the time of the meeting. Clinical trial information: NCT05655312 .
603 SUPRAME: a phase 3 trial evaluating IMA203 PRAME-directed TCR T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma
Moser, Justin, Amaria, Rodabe N, Warner, Allison Betof, Chmielowski, Bartosz, Fecher, Leslie A, Chandrasekaran, Sanjay, Chen, Ruqin, Cowey, Charles L, Daniels, Gregory A, Daud, Adil, Dimitrova, Maya, Dudek, Arkadiusz Z, Haugh, Alexandra, Hernandez-Aya, Leonel, Hu-Lieskovan, Siwen, Hurwitz, Michael E, Isaacs, James M, Karapetyan, Lilit, Lee, Sylvia, Mammen, Joshua MV, Mckean, Meredith, Mitchell, Tara C, Moschos, Stergios J, Naqash, Abdul Rafeh, Olson, Daniel J, Olszanski, Anthony J, Patel, Sapna P, Poklepovic, Andrew S, Robert, Caroline, Schadendorf, Dirk, Seedor, Rino S, Seetharam, Mahesh, Smithy, James W, Solomon, Benjamin M, Taylor, Matthew H, Terhune, Julia H, Viray, Hollis A, Whitman, Eric D, Wu, Richard, Xing, Yan, Krishna, Delfi, Mayer-Mokler, Andrea, Pankov, Dmitry, Britten, Cedrik M, Luke, Jason J, Moser, Justin, Amaria, Rodabe N, Warner, Allison Betof, Chmielowski, Bartosz, Fecher, Leslie A, Chandrasekaran, Sanjay, Chen, Ruqin, Cowey, Charles L, Daniels, Gregory A, Daud, Adil, Dimitrova, Maya, Dudek, Arkadiusz Z, Haugh, Alexandra, Hernandez-Aya, Leonel, Hu-Lieskovan, Siwen, Hurwitz, Michael E, Isaacs, James M, Karapetyan, Lilit, Lee, Sylvia, Mammen, Joshua MV, Mckean, Meredith, Mitchell, Tara C, Moschos, Stergios J, Naqash, Abdul Rafeh, Olson, Daniel J, Olszanski, Anthony J, Patel, Sapna P, Poklepovic, Andrew S, Robert, Caroline , Schadendorf, Dirk, Seedor, Rino S, Seetharam, Mahesh, Smithy, James W, Solomon, Benjamin M, Taylor, Matthew H, Terhune, Julia H, Viray, Hollis A, Whitman, Eric D, Wu, Richard, Xing, Yan, Krishna, Delfi, Mayer-Mokler, Andrea, Pankov, Dmitry, Britten, Cedrik M, Luke, Jason J

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: A687-A687

10.1136/jitc-2025-sitc2025.0603 Get It

NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Zaid, Mohammad Abu , Achufusi, Amaka, Armand, Philippe , Bermas, Bonnie L. , Braaten, Tawnie , Chokshi, Saurin , Crees, Zachary , Davies, Marianne, Deng, Changchun , Gesthalter, Yaron , Jallouk, Andrew , Khalil, Maya, Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Patel, Sandip Pravin , Prosek, Jason, Reddy, Sunil , Reid, Pankti , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Zucker, Stephen D. , Lyons, Megan , Hang, Lisa, Ryder, Mabel , Berkenstock, Meghan , Bermas, Bonnie , Budde, Lihua E. , Jain, Michael D. , Jain, Prantesh , Kaffenberger, B , Lechner, Melissa G , Li, Tianhong , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Oluwole, Olalekan O. , Ryan, John, Salman, Huda , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G , Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 13, 2024 | Volume: 22 | Issue: 9 | Pages: 582-592

10.6004/jnccn.2024.0057 | PMID 39536465 Get It

The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Johnson, Douglas B. , Albertini, Mark R. , Barker, Christopher A. , Bateni, Sarah B. , Baumgartner, Joel , Bichakjian, Christopher K. , Chandra, Sunandana , DiMaio, Dominick J. , Dronca, Roxana , Fleming, Martin D. , Galan, Anjela , Guild, Samantha, Hyngstrom, John , Karakousis, Giorgos C. , Kendra, Kari , Lange, Julie R., Lanning, Ryan M. , Logan, Theodore F. , Ott, Patrick A. , Ross, Merrick I. , Skitzki, Joseph J. , Smith, Emily , Tsai, Katy K., Wuthrick, Evan , Xing, Yan, McMillian, Nicole R., Espinosa, Sara, Olson, Daniel J. , Swetter, Susan M. , Bhatia, Shailender , Boland, Genevieve M. , Chmielowski, Bartosz , Fields, Ryan C. , Kiuru, Maija H. , Olson, Daniel, Olszanski, Anthony J. , Rothermel, Luke D. , Salama, April K.S. , Sharma, Rohit R. , Xing, Yan

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 26, 2024 | Volume: 22 | Issue: 5 | Pages: 290-298

10.6004/jnccn.2024.0036 | PMID 39019054 Get It

The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous ) provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients. These NCCN Guidelines Insights focus on the update to neoadjuvant systemic therapy options and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Cutaneous Melanoma.
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Kottschade, Lisa A. , Pond, Gregory R. , Olszanski, Anthony J. , Zakharia, Yousef , Domingo‐Musibay, Evidio , Hauke, Ralph J. , Curti, Brendan D. , Schober, Sarah , Milhem, Mohammed , Block, Matthew S. , Pond, Gregory Russell , Milhem, Mohammed M , Block, Matthew S , Hieken, Tina J , McWilliams, Robert R , Olszanski, Anthony J , Zakharia, Yousef , Hieken, Tina J. , McWilliams, Robert R.

Mayo Clinic

Clinical Cancer Research | March 31, 2023 | Volume: 29 | Issue: 12 | Pages: 2220-2225

10.1158/1078-0432.ccr-22-3207 | PMID 37000165 Get It

Abstract Purpose: Mucosal melanoma is a rare, aggressive form of melanoma with extremely high recurrence rates despite definitive surgical resection with curative intent. Currently there is no consensus on adjuvant therapy. Data on checkpoint inhibitors for adjuvant therapy are lacking. Patients and Methods: We performed a single-arm, multicenter clinical trial using “flip dose” ipilimumab (1 mg/kg q3w × 4 cycles), and nivolumab (3 mg/kg q3w × 4 cycles), then nivolumab 480 mg q4w × 11 cycles to complete a year of adjuvant therapy. Participants must have had R0/R1 resection ≤90 days before registration, no prior systemic therapy (adjuvant radiotherapy allowed), ECOG 0/1, and no uncontrolled autoimmune disease or other invasive cancer. Patients were recruited through the Midwest Melanoma Partnership/Hoosier Oncology Network. Results: From September 2017 to August 2021, 35 patients were enrolled. Of these, 29 (83%) had R0 resections, and 7 (20%) received adjuvant radiotherapy. Median age was 67 years, 21 (60.0%) female. Recurrence-free survival (RFS) rates at 1 and 2 years were 50% [95% confidence interval (CI), 31%–66%] and 37% (95% CI, 19%–55%), respectively. Overall survival rates at 1 and 2 years were 87% (95% CI, 68%–95%) and 68% (95% CI, 46%–83%), respectively. Median RFS was 10.3 months (95% CI, 5.7–25.8). Most common grade 3 toxicities were diarrhea (14%), hypertension (14%), and hyponatremia (11%), with no grade 4/5 toxicities. Conclusions: Flip-dose ipilimumab and nivolumab after resection of mucosal melanoma is associated with outcomes improved over that of surgical resection alone. Long-term follow-up, subgroup analyses and correlative studies are ongoing.
SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
Kottschade, Lisa A. , Pond, Gregory R. , Hauke, Ralph J. , Curti, Brendan D. , Schober, Sarah , Block, Matthew S. , Pond, Gregory Russell , Olszanski, Anthony J. , Zakharia, Yousef , Domingo‐Musibay, Evidio , Milhem, Mohammed , McWilliams, Robert R.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 9573-9573

10.1200/jco.2022.40.16_suppl.9573 Get It

9573 Background: Mucosal melanoma is a rare, highly aggressive form of melanoma with extremely high recurrence rates, despite definitive surgical resection. Median RFS has been reported to be 5.4m, with RFS rates at 1 and 2 years of 10%, and 0%, respectively (Lian B, Si L, Cui C, et al. Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma. Clinical Cancer Research 2013, 19(16):4488-4498). Currently there is no consensus on recommendations for adjuvant therapy. Data on the use of immune checkpoint inhibitors (ICI) adjuvantly is lacking. Methods: We performed a single arm, multicenter clinical trial using “flip dose” ipilimumab (1mg/kg q3w x4 cycles),and nivolumab (3 mg.kg q3w x4 cycles), then Nivolumab 480 mg q4w x 11 cycles to complete a year of adjuvant therapy. The primary endpoint was recurrence-free survival (RFS), and the study had 85% power to detect an improvement in RFS between 5.5 and 9.5 months using a one-sided log rank test. Participants must have had R0/R1 resection <90 days prior to registration, and no prior systemic therapy (adjuvant radiation allowed), ECOG 0/1, no uncontrolled significant autoimmune disease or other invasive cancer. Patients were recruited through the Midwest Melanoma Partnership/Hoosier Oncology Network. Results: From 9/17 to 8/21, 44 patients were approached at 6 centers. Of these 9 were ineligible, and 35 were enrolled. Of these, 29 (83%) had R0 resections, and 7 (20%) had adjuvant radiation prior to enrollment. As of Dec 2021, 31 patients have completed the treatment phase. Of the 35 patients treated on study, 20 patients have recurred (7 local, 5 distant, 3 regional, 5 sites unconfirmed), 6 stopped therapy due to adverse effects, and 8 have died. The mean age of patients was 65.8 years and 21 (60.0%) were female. The primary site of disease was vulvovaginal N=12 (32.4%) patients, sinonasal N= 11 (29.7%), anorectal N= 9 (24.3%) and other site N= 5 (13.5%). Adjuvant radiation had been given in 7 pts. Driver mutations were rare, with only 3 (8.6%) patients having a KIT mutation, and one patient (2.9%) each having a NRAS or BRAF mutation. RFS rates at 1 and 2 years were 50% (95% CI 31-66%) and 37% (95% CI 19-55%), with OS rates at 1 and 2 years of 87% (95% CI 68-95%) and 68% (95% CI 46-83%). Median RFS was 10.3 m (95% CI5.7-25.8). Most common grade 3 adverse events were diarrhea (14%), hypertension (14%), hyponatremia (11%), with no grade 4/5 toxicities. Conclusions: Flip dose ipilimumab and nivolumab after resection is associated with outcomes improved over previously reported outcomes in the absence of therapy. Long term follow up is ongoing as are subgroup analyses and correlative studies. Clinical trial information: NCT03241186.
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Achufusi, Amaka, Armand, Philippe , Bhatia, Shailender , Chokshi, Saurin , Davies, Marianne, Elshoury, Amro, Gesthalter, Yaron , Kaffenberger, Benjamin H. , Li, Tianhong , Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Oluwole, Olalekan O. , Patel, Sandip Pravin , Patil, Pradnya D. , Reddy, Sunil , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Lyons, Megan , Dwyer, Mary A., Hang, Lisa, Oluwole, Olalekan O , Kaffenberger, B , Ryder, Mabel , Berkenstock, Meghan , Budde, Lihua E. , Hegde, Aparna , Jain, Michael D. , Lechner, Melissa G , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 7, 2022 | Volume: 20 | Issue: 4 | Pages: 387-405

10.6004/jnccn.2022.0020 | PMID 35390769 Get It

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visitNCCN.org.
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021
Thompson, John A. , Albertini, Mark R. , Barker, Christopher A. , Baumgartner, Joel , Boland, Genevieve M. , DiMaio, Dominick J. , Durham, Alison B. , Fleming, Martin D. , Galan, Anjela , Gastman, Brian , Grossmann, Kenneth F. , Guild, Samantha, Holder, Ashley M. , Johnson, Douglas B. , Karakousis, Giorgos C. , Kendra, Kari , Lange, Julie R., Lanning, Ryan M. , Ott, Patrick A. , Ross, Merrick I. , Skitzki, Joseph J. , Sosman, Jeffrey A. , Wuthrick, Evan , McMillian, Nicole R., Engh, Anita M. , Swetter, Susan M. , Chmielowski, Bartosz , Fields, Ryan C. , Joseph, Richard W. , Margolin, Kim , Olszanski, Anthony J. , Salama, April K.S. , Sharma, Rohit R. , Boland, Genevieve

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 26, 2021 | Volume: 19 | Issue: 4 | Pages: 364-376

10.6004/jnccn.2021.0018 | PMID 33845460 Get It

Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways for treatment of microscopic satellitosis (added in v2.2020), and the following Principles sections: Molecular Testing (added in v2.2019), Systemic Therapy Considerations (added in v2.2020), and Brain Metastases Management (added in v3.2020). The v1.2021 update included additional modifications of these sections and notable revisions to Principles of: Pathology, Surgical Margins for Wide Excision of Primary Melanoma, Sentinel Lymph Node Biopsy, Completion/Therapeutic Lymph Node Dissection, and Radiation Therapy. These NCCN Guidelines Insights discuss the important changes to pathology and surgery recommendations, as well as additions to systemic therapy options for patients with advanced disease.
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors
Hong, David S. , Rixe, Olivier, Chiu, Vi K., Forde, Patrick M., Dragovich, Tomislav, Lou, Yanyan , Nayak-Kapoor, Asha , Leidner, Rom , Atkins, James N., Collaku, Agron , Fox, Floyd E., Marshall, Margaret A. , Forde, Patrick M. , Olszanski, Anthony J , Hong, David S , Forde, Patrick , Rixe, Olivier, Chiu, Vi K., Dragovich, Tomislav, Lou, Yanyan , Nayak-Kapoor, Asha , Leidner, Rom , Atkins, James N., Collaku, Agron , Fox, Floyd E., Marshall, Margaret A.

Mayo Clinic

Clinical Cancer Research | November 9, 2021 | Volume: 28 | Issue: 3 | Pages: 479-488

10.1158/1078-0432.ccr-21-2781 | PMID 34753777 Get It

Abstract Purpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with the checkpoint inhibitor nivolumab in patients with locally advanced or metastatic solid tumors. Patients and Methods: This was a multicenter, dose-finding (phase I), and dose expansion (phase II) study (NCT02705105) in patients with locally advanced or metastatic solid tumors. There were no dose-limiting toxicities in phase I with mogamulizumab 1 mg/kg every week for cycle 1 followed by 1 mg/kg every 2 weeks plus nivolumab 240 mg every 2 weeks intravenously, and cohort expansion occurred at this dose level. Results: All 114 patients treated with mogamulizumab 1 mg/kg plus nivolumab 240 mg in phases I (n = 4) and II (n = 110) were assessed for safety and efficacy. Mogamulizumab plus nivolumab showed acceptable safety and tolerability. Objective response rate was 10.5% [95% confidence interval (CI), 5.6–17.7; 3 complete and 9 partial responses]. Disease control rate was 36.8%. Median duration of response was 14.4 months. Median progression-free survival was 2.6 (95% CI, 2.3–3.1) months, and median overall survival was 9.5 (95% CI, 5.9–13.5) months. Conclusions: Combination of mogamulizumab with nivolumab for treatment of patients with locally advanced or metastatic solid tumors did not result in enhanced efficacy. Tolerability of mogamulizumab 1 mg/kg plus nivolumab 240 mg was acceptable.